Tomorrow's Cell
Therapies, Today®
Pluristyx provides induced pluripotent stem cells and the expertise to accelerate the development and commercialization of revolutionary cellular therapies.
We Simplify the Stem Cell Therapy
Development Process
We Simplify the Stem Cell Therapy
Development Process
Why Pluristyx?
Pluristyx's innovative technologies, provides clients with the necessary expertise and tools to support and accelerate the development and commercialization of cellular products.
Our iPSC platform offers our clients a single point of access to our research and clinical grade stem cells, proprietary gene edits and end-to-end support throughout the product development pathway.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
End-to-End Solutions
With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based products, Pluristyx can assist you at any stage in your product development workflow.
Gene Edits
Offering an array of gene editing technologies and our proprietary FailSafe® edit resulting in unparalleled functional control of commercial products.
Clinical Path iPSC
Leading provider of gene-edited iPSC and cell therapy solutions, accelerating the path to clinic and providing the best route to commercialization.
Scientific Expertise
Veteran expertise from industry leaders in the field of stem cell biology, developmental genetics and cell therapy.
Try Before You Buy
Would you like to experience our technology firsthand before committing to a license agreement? We welcome you to have access to our various product offerings before you purchase a commercial license.
Your Problems, Our Solution
To overcome any obstacle you’re facing, Pluristyx offers a novel iPSC platform for rapid, efficacious, and high-quality iPS cell therapy development, can turn your bold ideas into reality.
Your Problems,
Our Solution
To overcome any obstacle you’re facing, Pluristyx offers a novel platform for rapid, efficacious, and high-quality iPSC therapy development, can turn your bold ideas into reality.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
About Pluristyx
Pluristyx offers an enlarged portfolio of unique and effective non-modified and genetically engineered iPSC-based technologies and related services to provide end-to-end client support throughout the product lifecycle.
Latest News
Pluristyx Collaborates with Breakthrough T1D to Make "Immune-Cloaked" and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies
Seattle, WA – November 17, 2025 – Pluristyx announced today the launch of a project up to $1.4 million, supported and funded by Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization. The project...
Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics
SEATTLE, WA – November 5, 2025 – Pluristyx, Inc., a leading biotechnology company specializing in tools and technologies for the development of induced pluripotent stem cell (iPSC)-based therapies, today announced the execution of two significant commercial clinical use licensing agreements....
Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions
SEATTLE, WA & TELFORD, PA – September 24, 2025 – Pluristyx, Inc. and Solesis, LLC today announced the signing of a Memorandum of Understanding (MOU) establishing their strategic collaboration. The primary objective is to optimize a combination of technologies to...